Scientific discovery has always been a deeply human enterprise, combining creativity, accumulated knowledge, teamwork and experimental ingenuity. Yet it is constrained by what scientists can collectively read, analyse and propose. Two papers in Nature, one by Gottweis et al.1 and one by Ghareeb et al.2, test how much further these capabilities can be pushed by multi-agent AI tools — systems consisting of several autonomous AI agents that cooperate to solve complex problems.
Competing Interests
O.E. is a co-founder of and stockholder in Volastra Therapeutics; holds stock in Freenome; serves on the Scientific Advisory Boards of and holds stock options in Owkin, Harmonic Discovery and Exai; and serves on the Scientific Advisory Board of Canary Biosciences. He has received research funding from Eli Lilly, Janssen/Johnson & Johnson, Sanofi, AstraZeneca and Volastra Therapeutics.
